• 1
    Yoshida Y. Hypothesis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia 1993;7: 1446.
  • 2
    Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995;86: 26876.
  • 3
    Hellstrom-Lindberg E, Kanter-Lewensohn L, Ost A. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk Res 1997;21: 41525.
  • 4
    Raza A, Gregory SA, Preisler HD. The myelodysplastic syndromes in 1996: complex stem cell disorders confounded by dual actions of cytokines. Leuk Res 1996;20: 88190.
  • 5
    Bouscary D, De Vos J, Guesnu M, Jondeau K, Viguier F, Melle J et al. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia 1997;11: 83945.
  • 6
    Rajapaksa R, Ginzton N, Rott LS, Greenberg PL. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 1996;11: 427587.
  • 7
    Nagler A, Binet C, Mackichan ML, Negrin R, Bangs C, Donlon T et al. Impact of marrow cytogenetics and morphology on in vitro hematopoiesis in the myelodysplastic syndromes: comparison between recombinant human granulocyte colony-stimulating factor (CSF) and granulocyte-monocyte CSF. Blood 1990;76: 1299307.
  • 8
    Parker JE, Mufti GJ. Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes. Br J Haematol 1998;10: 22030.
  • 9
    Greenberg PL. Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Leuk Res 1998;22: 112336.
  • 10
    Claessens YE, Bouscary D, Dupont JM, Picard F, Melle J, Gisselbrecht S et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood 2002;99: 1594601.
  • 11
    Mundle S, Venugopal P, Shetty V, Ali A, Chopra H, Handa H et al. The relative extent and propensity of CD34+ vs. CD34− cells to undergo apoptosis in myelodysplastic marrows. Int J Hematol 1999;69: 1529.
  • 12
    Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000;96: 39328.
  • 13
    Josefsen D, Myklebust JH, Lynch DH, Stokke T, Blomhoff HK, Smeland EB. Fas ligand promotes cell survival of immature human bone marrow CD34+ CD38− hematopoietic progenitor cells by suppressing apoptosis. Exp Hematol 1999;27: 14519.
  • 14
    Mundle SD, Mativi BY, Bagai K, Feldman G, Cheema P, Gautam U et al. Spontaneous down-regulation of Fas-associated phosphatase-1 may contribute to excessive apoptosis in myelodysplastic marrows. Int J Hematol 1999;70: 8390.
  • 15
    Landowski TH, Gleason-Guzman MC, Dalton WS. Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood 1997;89: 185461.
  • 16
    Maurer AB, Ganser A, Buhl R, Seipelt G, Ottmann OG, Mentzel U et al. Restoration of impaired cytokine secretion from monocytes of patients with myelodysplastic syndromes after in vivo treatment with GM-CSF or IL-3. Leukemia 1993;7: 172833.
  • 17
    Bowen D, Yancik S, Bennett L, Culligan D, Resser K. Serum stem cell factor concentration in patients with myelodysplastic syndromes. Br J Haematol 1993;85: 636.
  • 18
    Fontenay-Roupie M, Bouscary D, Guesnu M, Picard F, Melle J, Lacombe C et al. Ineffective erythropoiesis in myelodysplastic syndromes: correlation with Fas expression but not with lack of erythropoietin receptor signal transduction. Br J Haematol 1999;106: 46473.
  • 19
    Lepelley P, Grardel N, Erny O, Iaru T, Obein V, Cosson A et al. Fas/APO-1 (CD95) expression in myelodysplastic syndromes. Leuk Lymphoma 1998;30: 30712.
  • 20
    Mundle SD, Reza S, Ali A, Mativi Y, Shetty V, Venugopal P et al. Correlation of tumor necrosis factor alpha (TNF alpha) with high Caspase 3-like activity in myelodysplastic syndromes. Cancer Lett 1999;140: 2017.
  • 21
    Kitagawa M, Yamaguchi S, Takahashi M, Tanizawa T, Hirokawa K, Kamiyama R. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Leukemia 1998;12: 48692.
  • 22
    Sawanobori M, Yamaguchi S, Hasegawa M, Inoue M, Suzuki K, Kamiyama R et al. Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes. Leuk Res 2003;27: 58391.
  • 23
    Kitagawa M, Saito I, Kuwata T, Yoshida S, Yamaguchi S, Takahashi M et al. Overexpression of tumor necrosis factor (TNF) – and interferon (IFN) – by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 1997;11: 204954.
  • 24
    Maciejewski JP, Selleri C, Anderson S, Young N. Fas antigen expression in CD34+ human bone marrow cells is induced by interferon- and tumor necrosis a and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 1995;85: 318390.
  • 25
    Gersuk GM, Beckham C, Loken MR, Kiener P, Anderson JE, Farrand A et al. A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 1998;103: 17688.
  • 26
    Shetty V, Mundle S, Alvi S, Showel M, Broady-Robinson L, Dar S et al. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res 1996;20: 891900.
  • 27
    Dar S, Mundle S, Andric T, Qawi H, Shetty V, Reza S et al. Biological characteristics of myelodysplastic syndrome patients who demonstrated high versus no intramedullary apoptosis. Eur J Haematol 1999;62: 904.
  • 28
    Verhoef GE, De Schouwer P, Ceuppens JL, Van Damme J, Goossens W, Boogaerts MA. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia 1992;6: 126872.
  • 29
    Musto P, Matera R, Minervini MM, Checchia-de Ambrosio C, Bodenizza C, Falcone A et al. Low serum levels of tumor necrosis factor and interleukin-1 beta in myelodysplastic syndromes responsive to recombinant erythropoietin. Haematologica 1994;79: 2658.
  • 30
    Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Span L et al. Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Int J Hematol 1996;63: 26578.
  • 31
    Peddie CM, Wolf CR, McLellan LI, Collins AR, Bowen DT. Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-alpha concentration. Br J Haematol 1997;99: 62531.
  • 32
    Kiener PA, Davis PM, Starling GC, Mehlin C, Klebanoff SJ, Ledbetter JA et al. Differential induction of apoptosis by Fas–Fas ligand interactions in human monocytes and macrophages. J Exp Med 1997;185: 15116.
  • 33
    Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F et al. Fas ligand in human serum. Nat Med 1996;2: 31722.
  • 34
    Krammer PH, Dhein J, Walczak H, Behrmann I, Mariani S, Matiba B et al. The role of APO-1-mediated apoptosis in the immune system. Immunol Rev 1994;142: 17591.
  • 35
    De Maria R, Testa U, Luchetti L, Zeuner A, Stassi G, Pelosi E et al. Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis. Blood 1999;93: 796803.
  • 36
    Dai CH, Price JO, Brunner T, Krantz SB. Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon gamma to produce erythroid cell apoptosis. Blood 1998;91: 123542.
  • 37
    Rosenfeld C, Bedell C. Pilot study of recombinant human soluble tumor necrosis factor receptor (TNFR. Fc) in patients with low risk myelodysplastic syndrome. Leuk Res 2002;26: 7214.
  • 38
    Coutinho LH, Geary CG, Chang J, Harrison C, Testa NG. Functional studies of bone marrow haemopoietic and stromal cells in the myelodysplastic syndrome (MDS). Br J Haematol 1990;75: 1625.
  • 39
    Aizawa S, Nakano M, Iwase O, Yaguchi M, Hiramoto M, Hoshi H et al. Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro. Leuk Res 1999;23: 23946.
  • 40
    Deeg HJ, Beckham C, Loken MR, Bryant E, Lesnikova M, Shulman HM et al. Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leuk Lymphoma 2000;37: 40514.
  • 41
    Bogdanovic Ad Trpinac DP, Jankovic GM, Bumbasirevic VZ, Obradovic M, Colovic MD. Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment. Leukemia 2001;11: 6569.
  • 42
    Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood 2001;98: 305865.
  • 43
    Barrett J, Saunthararajah Y, Molldrem J. Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin Hematol 2000;37: 1529.
  • 44
    Parker JE, Fishlock KL, Mijovic A, Czepulkowski B, Pagliuca A, Mufti GJ. Low-risk myelodysplastic syndromes is associated with excessive apoptosis and an increased ratio of pro-versus anti-apoptotic bcl-2-related proteins. Br J Haematol 1998;103: 107582.
  • 45
    Sloand EM, Kim S, Fuhrer M, Risitano AM, Nakamura R, Maciejewski JP et al. Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities. Blood 2002;100: 442732.
  • 46
    Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997;99: 690705.
  • 47
    Killick SB, Mufti G, Cavenagh JD, Mijovic A, Peacock JL, Gordon-Smith EC et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with ‘low-risk’ myelodysplasia. Br J Haematol 2003;120: 67984.
  • 48
    Smith MA, Smith JG. The occurrence subtype and significance of haemopoietic inhibitory T cells (HIT cells) in myelodysplasia: an in vitro study. Leuk Res 1991;15: 597601.
  • 49
    Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 1998; 102 (5):131422.
  • 50
    Hamann D, Roos MT, Van Lier RA. Faces and phases of human CD8 T-cell development. Immunol Today 1999;20: 17780.
  • 51
    Melenhorst JJ, Eniafe R, Follmann D, Nakamura R, Kirby M, Barrett AJ. Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome. Br J Haematol 2002;119: 97105.
  • 52
    Epperson DE, Nakamura R, Saunthararajah Y, Melenhorst J, Barrett AJ. Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res 2001;25: 107583.
  • 53
    Matsutani T, Yoshioka T, Tsuruta Y, Shimamoto T, Ohyashiki JH, Suzuki R et al. Determination of T-cell receptors of clonal CD8-positive T–cells in myelodysplastic syndrome with erythroid hypoplasia. Leuk Res 2003;27: 30512.
  • 54
    Kook H, Zeng W, Guibin C, Kirby M, Young NS, Maciejewski JP. Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp Hematol 2001;29: 12707.
  • 55
    Culligan DJ, Cachia P, Whittaker J, Jacobs A, Padua RA. Clonal lymphocytes are detectable in only some cases of MDS. Br J Haematol 1992;81: 34652.
  • 56
    Kroef MJ, Fibbe WE, Mout R, Jansen RP, Haak HL, Wessels JW et al. Myeloid but not lymphoid cells carry the 5q deletion: polymerase chain reaction analysis of loss of heterozygosity using mini-repeat sequences on highly purified cell fractions. Blood 1993;8: 184954.
  • 57
    Kibbelaar RE, Van Kamp H, Dreef EJ, De Groot-Swings G, Kluin-Nelemans JC, Beverstock GC et al. Combined immunophenotyping and DNA in situ hybridization to study lineage involvement in patients with myelodysplastic syndromes. Blood 1992;79: 18238.
  • 58
    Melenhorst JJ, Fibbe WE, Smits S, Willemze R, Landegent JE. Aplastic anaemia patients with clonal X-chromosome inactivation pattern in haemopoietic cells exhibit polyclonal TCRgamma and IgH gene rearrangements. Br J Haematol 1996;93: 32632.
  • 59
    Maciejewski JP, Hibbs JR, Anderson S, Katevas P, Young NS. Bone marrow and peripheral blood lymphocyte phenotype in patients with bone marrow failure. Exp Hematol 1994;22: 110210.
  • 60
    Melenhorst JJ, Van Luxemburg-Heijs SA, Landegent JE, Willemze R, Fibbe WE, Falkenburg JH. Aplastic anaemia in donor cells 14 years after bone-marrow transplant. Lancet 1999;353: 20378.
  • 61
    Dietrich PY, Caignard A, Lim A, Chung V, Pico JL, Pannetier C et al. In vivo T-cell clonal amplification at time of acute graft-versus-host disease. Blood 1994;84: 281520.
  • 62
    Hong J, Zang YC, Tejada-Simon MV, Kozovska M, Li S, Singh RA et al. A common TCR V-D-J sequence in V beta 13·1 T cells recognizing an immunodominant peptide of myelin basic protein in multiple sclerosis. J Immunol 1999;163: 35308.
  • 63
    Mima T, Ohshima S, Sasai M, Nishioka K, Shimizu M, Murata N et al. Dominant and shared T cell receptor beta chain variable regions of T cells inducing synovial hyperplasia in rheumatoid arthritis. Biochem Biophys Res Commun 1999;263: 17280.
  • 64
    Raza A. Hypothesis: myelodysplastic syndromes may have a viral etiology. Int J Hematol 1998;68: 24556.
  • 65
    Kochenderfer JN, Kobayashi S, Wieder ED, Su C, Molldrem JJ. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 2002;100: 363945.
  • 66
    Martinez-Jaramillo G, Flores-Figueroa E, Gomez-Morales E, Sanchez-Valle E, Mayani H. Tumor necrosis factor-alpha levels in long-term marrow cultures from patients with aplastic anemia: modulation by granulocyte-macrophage colony-stimulating factor. Am J Hematol 2001;68: 1448.
  • 67
    Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med 1997;336: 136572.
  • 68
    Sloand E, Kim S, Maciejewski JP, Tisdale J, Follmann D, Young NS. Intracellular interferon-gamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. Blood 2002;100: 118591.
  • 69
    Zeng W, Nakao S, Takamatsu H, Yachie A, Takami A, Kondo Y et al. Characterization of T-cell repertoire of the bone marrow in immune-mediated aplastic anemia: evidence for the involvement of antigen-driven T-cell response in cyclosporine-dependent aplastic anemia. Blood 1999;93: 300816.
  • 70
    Hamblin TJ. Immunological abnormalities in myelodysplastic syndromes. Semin Hematol 1996;33: 15062.
  • 71
    Enright H, Jacob HS, Vercellotti G, Howe R, Belzer M, Miller W. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol 1995;91: 4038.
  • 72
    Castro M, Conn DL, Su WP, Garton JP. Rheumatic manifestations in myelodysplastic syndromes. J Rheumatol 1991;18: 7217.
  • 73
    Billstrom R, Johansson H, Johansson B, Mitelman F. Immune-mediated complications in patients with myelodysplastic syndromes – clinical and cytogenetic features. Eur J Haematol 1995;55: 428.
  • 74
    Okamoto T, Okada M, Mori A, Saheki K, Takatsuka H, Wada H et al. Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients. Int J Hematol 1997;66: 34551.
  • 75
    Mufti GJ, Figes A, Hamblin TJ, Oscier DG, Copplestone JA. Immunological abnormalities in myelodysplastic syndromes. I. Serum immunoglobulins and autoantibodies. Br J Haematol 1986;63: 1437.
  • 76
    Economopoulos T, Economidou J, Giannopoulos G, Terzoglou C, Papageorgiou E, Dervenoulas J et al. Immune abnormalities in myelodysplastic syndromes. J Clin Pathol 1985;38: 90811.
  • 77
    Giannouli S, Voulgarelis M, Zintzaras E, Tzioufas AG, Moutsopoulos HM. Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study. Rheumatology (Oxf) 2004;43: 62632.
  • 78
    Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51: 18999.
  • 79
    Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89: 207988.
  • 80
    Fujita T, Sakakibara J, Sudo Y, Miyamoto M, Kimura Y, Taniguchi T. Evidence for a nuclear factor (s), IRF-1, mediating induction and silencing properties to human IFN-beta gene regulatory elements. EMBO J 1988;7: 3397405.
  • 81
    Miyamoto M, Fujita T, Kimura Y, Maruyama M, Harada H, Sudo Y et al. Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-beta gene regulatory elements. Cell 1988;54: 90313.
  • 82
    Tanaka N, Ishihara M, Kitagawa M, Harada H, Kimura T, Matsuyama T et al. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 1994;77: 82939.
  • 83
    Romeo G, Fiorucci G, Chiantore MV, Percario ZA, Vannucchi S, Affabris E. IRF-1 as a negative regulator of cell proliferation. J Interferon Cytokine Res 2002;22: 3947.
  • 84
    Willman CL, Sever CE, Pallavicini MG, Harada H, Tanaka N, Slovak ML et al. Deletion of IRF-1, mapping to chromosome 5q31·1, in human leukemia and preleukemic myelodysplasia. Science 1993;259: 96871.
  • 85
    Harada H, Kondo T, Ogawa S, Tamura T, Kitagawa M, Tanaka N et al. Accelerated exon skipping of IRF-1mRNA in human myelodysplasia/leukemia; a possible mechanism of tumor suppressor inactivation. Oncogene 1994;9: 331320.
  • 86
    Ogasawara K, Hida S, Azimi N, Tagaya Y, Sato T, Yokochi-Fukuda T et al. Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. Nature 1998;391: 7003.
  • 87
    Kroger A, Koster M, Schroeder K, Hauser H, Mueller PP. Activities of IRF-1. J Interferon Cytokine Res 2002;22: 514.
  • 88
    Salkowski CA, Kopydlowski K, Blanco J, Cody MJ, McNally R, Vogel SN. IL-12 is dysregulated in macrophages from IRF-1 and IRF-2 knockout mice. J Immunol 1999;163: 152936.
  • 89
    Blanco JC, Contursi C, Salkowski CA, DeWitt DL, Ozato K, Vogel SN. Interferon regulatory factor (IRF)-1 and IRF-2 regulate interferon gamma-dependent cyclooxygenase 2 expression. J Exp Med 2000;191: 213144.
  • 90
    Giannouli S, Tzoanopoulos D, Ritis K, Kartalis G, Moutsopoulos HM, Voulgarelis M. Autoimmune manifestations in human myelodysplasia: a positive correlation with interferon regulatory factor-1 (IRF-1) expression. Ann Rheum Dis 2004;63: 57882.
  • 91
    Lechleitner S, Gille J, Johnson DR, Petzelbauer P. Interferon enhances tumor necrosis factor-induced vascular cell adhesion molecule 1 (CD106) expression in human endothelial cells by an interferon-related factor 1-dependent pathway. J Exp Med 1998;187: 202330.
  • 92
    Coll-Vinent B, Cebrian M, Cid MC, Font C, Esparza J, Juan M et al. Dynamic pattern of endothelial cell adhension molecule expression in muscle and perineural vessels from patients with classic polyarteritis nodosa. Arthritis Rheum 1998;41: 43544.
  • 93
    Cid MC, Cebrian M, Font C, Coll-Vinent B, Hernandez-Rodriguez J, Esparza J et al. Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis: inflammation-induced angiogenesis as the preferential site of leukocyte–endothelial cell interactions. Arthritis Rheum 2000;43: 18494.
  • 94
    Tada Y, Ho A, Matsuyama T, Mak TW. Reduced incidence and severity of antigen-induced autoimmune diseases in mice lacking interferon regulatory factor-1. J Exp Med 1997;185: 2318.
  • 95
    Hamidou MA, Boumalassa A, Larroche C, El Kouri D, Bletry O, Grolleau JY. Systemic medium-sized vessel vasculitis associated with chronic myelomonocytic leukemia. Semin Arthritis Rheum 2001;31: 11926.